Details

Autor(en) / Beteiligte

• Heinze-Milne, Stefan D.
• Banga, Shubham
• Howlett, Susan E.

Titel

Frailty and cytokines in preclinical models: Comparisons with humans

Ist Teil von

• Mechanisms of ageing and development, 2022-09, Vol.206, p.111706-111706, Article 111706

Ort / Verlag

Elsevier B.V

Erscheinungsjahr

2022

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Chronic low-grade elevations of blood-borne cytokines/chemokines in older age tend to associate with frailty in humans. This persistent inflammation is often called “inflammageing” and likely contributes to frailty progression. Preclinical models such as ageing and/or genetically modified mice offer a unique opportunity to mechanistically study how these inflammatory mediators affect frailty. In this review, we summarize and contrast evidence relating cytokines/chemokines to frailty in humans and in mouse models of frailty. In humans and mice, higher levels of the pro-inflammatory cytokine interleukin-6 regularly increased in proportion to the degree of frailty. Evidence linking other cytokines/chemokines to frailty in humans and mice is less certain. The chemokines CXCL-10 and monocyte chemoattractant protein-1 related to frailty across both species, but evidence is limited and inconsistent. Several other cytokines/chemokines, including tumour necrosis factor-α relate to frailty in humans or in mice, but evidence to date is species- and tissue-dependent. It is important for future studies to validate common mechanistic inflammatory biomarkers of frailty between humans and mice. Achieving this goal will accelerate the search for drugs to treat frailty. [Display omitted] •Circulating cytokine and chemokine levels relate to frailty in humans and mice.•The pro-inflammatory cytokine IL-6 most closely related to frailty in both species.•Chemokines CXCL-10 and MCP-1 may relate to the degree of frailty across species.•Links between frailty and cytokines or chemokines can differ between the sexes.•Identification of other cytokine biomarkers may create sex-specific frailty assays.